TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$58 Million


Follow-on Offering

Lead Left Bookrunner, July 2020


CytoSorbents Corporation is a critical care immunotherapy company focused on reducing uncontrolled inflammation in hospitalized patients with its lead product, CytoSorb. CytoSorb is an extracorporeal blood purification technology that uses porous polymer beads to remove toxic substances from the blood through a process called adsorption. The device filters pro-inflammatory cytokines thus reducing the “cytokine storm” that results when cytokines are massively overproduced in response to a severe infection, often leading to organ failure and death. CytoSorb is approved in the EU as an extracorporeal cytokine filter to help treat hyperinflammatory conditions where cytokines are elevated (cytokine storm) and to remove rivaroxaban. CytoSorb can also prevent or treat organ failure associated with sepsis and other critical illnesses such as burn injury, acute respiratory distress syndrome, pancreatitis and trauma. The device also has utility during and after cardiac surgery, an indication evaluated in CTSO’s REFRESH 1 and 2 studies.